We have been significant STAAR shareholders for more than ten years and remain convicted in the significant value of the Company. The proposed sale of STAAR to Alcon for $28 per share significantly undervalues the Company, especially when considering the STAAR Board of Directors' rejection of Alcon's previous offer for $58 per share in cash only sixteen months ago. With recent positive projections and outlook released by management, we see no compelling reason to sell STAAR at this time. We are disappointed ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today highlighted commentary from numerous independent industry analysts who recognize that STAAR's merger with Alcon (SIX/NYSE: ALC) – and the compelling, certain, premium cash value it provides – is the best path forward for STAAR stockholders. Stephen Farrell, CEO of STAAR, said, "Prior to the Alcon. ...

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood†), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR†or the "Company†) (NASDAQ: STAA), today announced that it has published a presentation outlining why stockholders should vote on Broadwood's GREEN Proxy Card "AGAINST†the proposed acquisition of the Company by an affiliate of Alcon Inc. (NYSE: ALC) on the terms announced on August 5, 2025. The 81-pa. ...

Accessibility StatementSkip Navigation PHILADELPHIA, Oct. 1, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating the shareholder buyout offer made to STAAR Surgical Company (NASDAQ: STAA) ("STAAR" or the "Company") investors to determine whether the proposal is fair and provides sufficient monetary consideration for the Company's investors. Following the proposed transaction, STAAR shares will no longer be publicly traded. Click here to request additional information ab ...

GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) ("STAAR†), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced,. ...

NEW YORK, Sept. 27, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: STAAR Surgical Company (NASDAQ: STAA)’s sale to Alcon for $28.00 per share in cash. If you are a STAAR shareholder, click here to learn more about your rights and options. CyberArk Software Ltd. (NASDAQ: CYBR)’s sale to Palo Alto Networks for $45.00 in cash ...

PHILADELPHIA, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of STAAR Surgical Company (NASDAQ: STAA) (“STAAR” or the “Company”) shareholders to determine whether the proposal is fair to investors.  Click here for additional information: https://kaskelalaw.com/case/staar-surgical/  On August 5, 2025, STAAR announced that it had agreed to be acquired by Alcon at a price of $28.00 per share in cash. F ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the 45-day "window shop†period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE: ALC). The "window shop†period expired at 11:59 p.m., Eastern Time, on September 19, 2025, and no competing acquisition proposal was receive. ...

Yunqi Capital, an investment management firm and 5.1% shareholder of Staar Surgical Company (NASDAQ:STAA), announced its opposition to the company’s proposed sale to Alcon (NYSE:ALC) on the terms announced on August 5. Yunqi Capital stated that it believes the $28 per ...

交易反对立场 - 云资本有限公司作为持有STAAR Surgical Company 5[1]1%股份的投资管理公司 公开反对STAAR Surgical Company出售给爱尔康公司的交易[1] 交易关键信息 - 拟议的出售交易由STAAR Surgical Company于2025年8月5日宣布[1] - 云资本有限公司于2025年9月22日发布了致STAAR其他股东的公开信以解释其反对立场[1] 公司身份说明 - 云资本有限公司及其关联公司和所建议的基金合称为"云资本"[1] - STAAR Surgical Company在纳斯达克上市 股票代码为STAA[1] - 收购方爱尔康公司在瑞士证券交易所和纽约证券交易所上市 股票代码为ALC[1]